API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Under the agreement, Kolinpharma will use its existing sales network and relationships with relevant clinical communities to market Iron Hydroxide Adipate Tartrate (IHAT), an oral iron supplementation product for iron deficiency, under its brand KIPFeR.
Lead Product(s): Iron Hydroxide Adipate Tartrate
Therapeutic Area: Hematology Product Name: KIPFeR
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Nemysis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 10, 2024
Details:
Under the agreement, Bruno will use its existing sales network and relationships with relevant clinical communities to market IHAT (iron hydroxide adipate tartrate), an oral iron supplementation product, under its own brand.
Lead Product(s): Iron Hydroxide Adipate Tartrate
Therapeutic Area: Hematology Product Name: IHAT
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bruno Farmaceutici
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 05, 2023
Details:
The patent claims describe methods for producing IHAT (Iron Hydroxide Adipate Tartrate), where Generally Recognised As Safe (GRAS) organic acids, and particularly Tartaric and Adipic acids, are used to modify the ferrihydrite nanocore of ferritin.
Lead Product(s): Iron Hydroxide Adipate Tartrate
Therapeutic Area: Hematology Product Name: IHAT-02
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2021